Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience

Amaç: İmmün trombositopeni (İTP), trombositlerin immün aracılı yıkım ile kalıcı veya geçici olarak 100x109/L altında olduğu bir hastalıktır. Selim hematolojik hastalıklar içinde yer almasına rağmen kanama komplikasyonları ölümcül olabilir. Hastalığın patofizyolojisi daha iyi anlaşılması ile son yıllarda kullanıma giren trombopoetin reseptör agonistleri, dirençli hastaların tedavisinde etkili bir seçenek olarak görünmektedir.Gereç ve Yöntemler: Bu çalışmada Ege Bölgesi'nde refrakter İTP tanısı ile eltrombopag ile tedavi edilen 8 farklı merkezden 40 hastanın retrospektif verileri incelenmiş ve değerlendirilmiştir. Bulgular: Çalışmada toplam yanıt oranı %87 idi ve trombositlerin 50x109/L'nin üzerine çıktığı medyan süre 19,5 gün saptandı. Tromboz için başka hiçbir ek risk faktörü bulunmayan bir hastada venöz sinüs trombozu gözlendi. On iki aydır tam yanıtlı izlenen ve düzensiz takibe gelen bir diğer hasta olası akut miyokard infarktüsü sonucu gelişen ani ölüm nedeni ile kaybedildi.Sonuç: Her ne kadar eltrombopag yanıtları tatmin edici olsa da, hızlı ilerleyen trombositemiye bağlı gelişecek tromboembolik olaylar açısından, yakın takip ve monitorizasyon gereklidir

Anahtar Kelime:

Konular: Hematoloji

İmmün Trombositopeni Tedavisinde Eltrombopag: Türkiye Ege Bölgesi Deneyimika

Öz:

Objective: Immune thrombocytopenia (ITP) is an immune-mediated disease characterized by transient or persistent decrease of the platelet count to less than 100x109/L. Although it is included in a benign disease group, bleeding complications may be mortal. With a better understanding of the pathophysiology of the disease, thrombopoietin receptor agonists, which came into use in recent years, seem to be an effective option in the treatment of resistant cases. This study aimed to retrospectively assess the efficacy, long-term safety, and tolerability of eltrombopag in Turkish patients with chronic ITP in the Aegean region of Turkey.Materials and Methods: Retrospective data of 40 patients with refractory ITP who were treated with eltrombopag in the Aegean region were examined and evaluated.Results: The total rate of response was 87%, and the median duration of response defined as the number of the platelets being over 50x109/L was 19.5 days. In one patient, venous sinus thrombosis was observed with no other additional risk factors due to or related to thrombosis. Another patient with complete response and irregular follow-up for 12 months was lost due to sudden death as the result of probable acute myocardial infarction.Conclusion: Although the responses to eltrombopag were satisfactory, patients need to be monitored closely for overshooting platelet counts as well as thromboembolic events

Anahtar Kelime:

Konular: Hematoloji

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, Grainger J, Greer I, Hunt BJ, Imbach PA, Lyons G, McMillan R, Rodeghiero F, Sanz MA, Tarantino M, Watson S, Young J, Kuter DJ. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168-186.
Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002;346:995-1008.
Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, Godeau B, Lechner K, Mazzucconi MG, McMillan R, Sanz MA, Imbach P, Blanchette V, Kühne T, Ruggeri M, George JN. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113:2386-2393.
Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA; American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011;117:4190-4207.
Kumar S, Diehn FE, Gertz MA, Tefferi A. Splenectomy for immune thrombocytopenic purpura: long term results and treatment of postsplenectomy relapse. Ann Hematol 2002;81:312-319.
McMillan R. Classical management of refractory adult immune (idiopathic) thrombocytopenic purpura. Blood Rev 2002;16:51-55.
Yang R, Han ZC. Pathogenesis and management of chronic idiopathic thrombocytopenic purpura: an update. Int J Hematol 2000;71:18-24.
Garnock-Jones KP, Keam SJ. Eltrombopag. Drugs 2009;69:567- 576.
Glaxo Smith Kline. Promacta (Eltrombopag) Prescribing Information. Research Triangle Park, NC, USA, Glaxo Smith Kline, 2012. Available at http://www.gsksource.com/gskprm/ en/US/adirect/gskprm?cmd=Product DetailPage&product_ id=1353688574915. Accessed 28 February 2013.
Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-214.
Katsutani S, Tomiyama Y, Kimura A, Miyakawa Y, Okamoto S, Okoshi Y, Ninomiya H, Kosugi H, Ishii K, Ikeda Y, Hattori T, Katsura K, Kanakura Y. Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension study. Int J Hematol 2013;98:323-330.
Tomiyama Y, Miyakawa Y, Okamoto S, Katsutani S, Kimura A, Okoshi Y, Ninomiya H, Kosugi H, Nomura S, Ozaki K, Ikeda Y, Hattori T, Katsura K, Kanakura Y. A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia. J Thromb Haemost 2012;10:799-806.
Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL, Bussel JB. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011;377:393-402.
Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, Brainsky A; EXTEND Study Group. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood 2013;121:537-545.
Zelcer S, Bussel JB. Thrombosis in patients with immune thrombocytopenic purpura (ITP): a case series. J Thromb Haemost 2003;1:1169 (abstract).
Ghanima W, Lee SY, Barsam S, Miller A, Sandset PM, Bussel JB. Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists. Br J Haematol 2012;158:811-814.
Douglas V, Tallman M, Cripe L, Peterson LC. Thrombopoietin administered during induction chemotherapy to patients with acute myeloid leukemia induces transient morphologic changes that may resemble chronic myeloproliferative disorders. Am J Clin Pathol 2002;117:844-850.
Cheng G. Eltrombopag, a thrombopoietin- receptor agonist in the treatment of adult chronic immune thrombocytopenia: a review of the efficacy and safety profile. Ther Adv Hematol 2012;3:155-164.

APA	Gediz F, PAYZİN B, KİPER H, KABUKÇU S, AKGÜN ÇAĞLIYAN G, kahraman s, SEVİNDİK Ö, CEYLAN C, Kadikoylu G, Sahin F, KESKİN A, ARSLAN Ö, ÖZCAN M, GÖRGÜN G, BOLAMAN A, BÜYÜKKEÇECİ F, Bilgir O, ALACACIOGLU I, vural f, TOMBULOĞLU M, Gokgoz Z, SAYDAM G (2015). Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience. , 323 - 328.
Chicago	Gediz Fusun,PAYZİN Bahriye,KİPER H Demet,KABUKÇU Sibel,AKGÜN ÇAĞLIYAN GÜLSÜM,kahraman selda,SEVİNDİK ÖMÜR GÖKMEN,CEYLAN CENGIZ,Kadikoylu Gurhan,Sahin Fahri,KESKİN Ali,ARSLAN Öykü,ÖZCAN MEHMET ALİ,GÖRGÜN Gülnur,BOLAMAN ALİ ZAHİT,BÜYÜKKEÇECİ Filiz,Bilgir Oktay,ALACACIOGLU INCI,vural filiz,TOMBULOĞLU Murat,Gokgoz Zafer,SAYDAM Güray Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience. (2015): 323 - 328.
MLA	Gediz Fusun,PAYZİN Bahriye,KİPER H Demet,KABUKÇU Sibel,AKGÜN ÇAĞLIYAN GÜLSÜM,kahraman selda,SEVİNDİK ÖMÜR GÖKMEN,CEYLAN CENGIZ,Kadikoylu Gurhan,Sahin Fahri,KESKİN Ali,ARSLAN Öykü,ÖZCAN MEHMET ALİ,GÖRGÜN Gülnur,BOLAMAN ALİ ZAHİT,BÜYÜKKEÇECİ Filiz,Bilgir Oktay,ALACACIOGLU INCI,vural filiz,TOMBULOĞLU Murat,Gokgoz Zafer,SAYDAM Güray Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience. , 2015, ss.323 - 328.
AMA	Gediz F,PAYZİN B,KİPER H,KABUKÇU S,AKGÜN ÇAĞLIYAN G,kahraman s,SEVİNDİK Ö,CEYLAN C,Kadikoylu G,Sahin F,KESKİN A,ARSLAN Ö,ÖZCAN M,GÖRGÜN G,BOLAMAN A,BÜYÜKKEÇECİ F,Bilgir O,ALACACIOGLU I,vural f,TOMBULOĞLU M,Gokgoz Z,SAYDAM G Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience. . 2015; 323 - 328.
Vancouver	Gediz F,PAYZİN B,KİPER H,KABUKÇU S,AKGÜN ÇAĞLIYAN G,kahraman s,SEVİNDİK Ö,CEYLAN C,Kadikoylu G,Sahin F,KESKİN A,ARSLAN Ö,ÖZCAN M,GÖRGÜN G,BOLAMAN A,BÜYÜKKEÇECİ F,Bilgir O,ALACACIOGLU I,vural f,TOMBULOĞLU M,Gokgoz Z,SAYDAM G Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience. . 2015; 323 - 328.
IEEE	Gediz F,PAYZİN B,KİPER H,KABUKÇU S,AKGÜN ÇAĞLIYAN G,kahraman s,SEVİNDİK Ö,CEYLAN C,Kadikoylu G,Sahin F,KESKİN A,ARSLAN Ö,ÖZCAN M,GÖRGÜN G,BOLAMAN A,BÜYÜKKEÇECİ F,Bilgir O,ALACACIOGLU I,vural f,TOMBULOĞLU M,Gokgoz Z,SAYDAM G "Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience." , ss.323 - 328, 2015.
ISNAD	Gediz, Fusun vd. "Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience". (2015), 323-328.

APA	Gediz F, PAYZİN B, KİPER H, KABUKÇU S, AKGÜN ÇAĞLIYAN G, kahraman s, SEVİNDİK Ö, CEYLAN C, Kadikoylu G, Sahin F, KESKİN A, ARSLAN Ö, ÖZCAN M, GÖRGÜN G, BOLAMAN A, BÜYÜKKEÇECİ F, Bilgir O, ALACACIOGLU I, vural f, TOMBULOĞLU M, Gokgoz Z, SAYDAM G (2015). Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience. Turkish Journal of Hematology, 32(4), 323 - 328.
Chicago	Gediz Fusun,PAYZİN Bahriye,KİPER H Demet,KABUKÇU Sibel,AKGÜN ÇAĞLIYAN GÜLSÜM,kahraman selda,SEVİNDİK ÖMÜR GÖKMEN,CEYLAN CENGIZ,Kadikoylu Gurhan,Sahin Fahri,KESKİN Ali,ARSLAN Öykü,ÖZCAN MEHMET ALİ,GÖRGÜN Gülnur,BOLAMAN ALİ ZAHİT,BÜYÜKKEÇECİ Filiz,Bilgir Oktay,ALACACIOGLU INCI,vural filiz,TOMBULOĞLU Murat,Gokgoz Zafer,SAYDAM Güray Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience. Turkish Journal of Hematology 32, no.4 (2015): 323 - 328.
MLA	Gediz Fusun,PAYZİN Bahriye,KİPER H Demet,KABUKÇU Sibel,AKGÜN ÇAĞLIYAN GÜLSÜM,kahraman selda,SEVİNDİK ÖMÜR GÖKMEN,CEYLAN CENGIZ,Kadikoylu Gurhan,Sahin Fahri,KESKİN Ali,ARSLAN Öykü,ÖZCAN MEHMET ALİ,GÖRGÜN Gülnur,BOLAMAN ALİ ZAHİT,BÜYÜKKEÇECİ Filiz,Bilgir Oktay,ALACACIOGLU INCI,vural filiz,TOMBULOĞLU Murat,Gokgoz Zafer,SAYDAM Güray Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience. Turkish Journal of Hematology, vol.32, no.4, 2015, ss.323 - 328.
AMA	Gediz F,PAYZİN B,KİPER H,KABUKÇU S,AKGÜN ÇAĞLIYAN G,kahraman s,SEVİNDİK Ö,CEYLAN C,Kadikoylu G,Sahin F,KESKİN A,ARSLAN Ö,ÖZCAN M,GÖRGÜN G,BOLAMAN A,BÜYÜKKEÇECİ F,Bilgir O,ALACACIOGLU I,vural f,TOMBULOĞLU M,Gokgoz Z,SAYDAM G Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience. Turkish Journal of Hematology. 2015; 32(4): 323 - 328.
Vancouver	Gediz F,PAYZİN B,KİPER H,KABUKÇU S,AKGÜN ÇAĞLIYAN G,kahraman s,SEVİNDİK Ö,CEYLAN C,Kadikoylu G,Sahin F,KESKİN A,ARSLAN Ö,ÖZCAN M,GÖRGÜN G,BOLAMAN A,BÜYÜKKEÇECİ F,Bilgir O,ALACACIOGLU I,vural f,TOMBULOĞLU M,Gokgoz Z,SAYDAM G Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience. Turkish Journal of Hematology. 2015; 32(4): 323 - 328.
IEEE	Gediz F,PAYZİN B,KİPER H,KABUKÇU S,AKGÜN ÇAĞLIYAN G,kahraman s,SEVİNDİK Ö,CEYLAN C,Kadikoylu G,Sahin F,KESKİN A,ARSLAN Ö,ÖZCAN M,GÖRGÜN G,BOLAMAN A,BÜYÜKKEÇECİ F,Bilgir O,ALACACIOGLU I,vural f,TOMBULOĞLU M,Gokgoz Z,SAYDAM G "Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience." Turkish Journal of Hematology, 32, ss.323 - 328, 2015.
ISNAD	Gediz, Fusun vd. "Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience". Turkish Journal of Hematology 32/4 (2015), 323-328.